Shifamed spinout and intraocular lens maker Atia Vision announced today that it closed the second tranche of a $20 million Series D financing.
Campbell, Calif.-based Atia Vision said in a news release that the funding round that was led by Cormorant Asset Management with participation from The Capital Partnership, AMED Ventures and Shangbay Capital.
The company said the financing is earmarked for its continued early clinical experience treating cataract patients, as well as the expansion of its facility. Atia Vision develops its intraocular lens to treat far-sightedness.
Atia Vision announced in May of last year that it had completed the first tranche of the $20 million Series D with investments from the same participants and the same intended use of proceeds.
“We are pleased to have early clinical evidence demonstrating accommodation, the ability of the eye to change its focus between distant and near objects,” Atia Vision president &…